Screening for liver scarring risk using noninvasive tests
Part of Digestive system clinical trials.
This study checks people who are at higher risk for liver scarring by using noninvasive tests. If those tests suggest significant scarring, the study may consider further testing, but not everyone will need a biopsy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 30 and 75 years old (or 40–75 for the general public)
- You can give informed consent for study testing
- You can read and write Danish (at-risk participants only)
- You have at least one risk factor: heavy past/current alcohol use, metabolic syndrome, or type 2 diabetes
- No clear signs of advanced liver disease like fluid buildup in the belly, confusion from liver disease, yellow skin/eyes, or large swollen veins in the food pipe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
This study tests how well primary care doctors can screen for advanced liver scarring in people with fatty liver from non-alcohol causes or from alcohol use. It may help find liver problems earlier so you can get the right follow-up.
This study aims to find a simple way to detect liver fibrosis, a condition where the liver becomes scarred, in people who have risk factors like being overweight, having type 2 diabetes, or drinking alcohol heavily. By identifying fibrosis early, it may help prevent more serious liver problems.
This study compares two non-invasive approaches to diagnose advanced liver scarring in people with non-alcohol-related fatty liver disease (NAFLD). It may help confirm which test strategy finds advanced scarring without needing a biopsy for everyone.
This study is for people with type 2 diabetes who may have early liver damage (fatty liver) but haven't yet developed severe scarring. It tests a simple screening program to find advanced liver fibrosis early, so it can be treated sooner.
This trial looks for better ways to detect liver scarring (fibrosis) in people with long-term liver disease. It may help find problems earlier.
Hear when a new Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.